Drugs / crefmirlimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06863233 | Mar 2025 → Mar 2028 expected | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | crefmirlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06863233 ↗ |
| Known as | Zirconium Zr 89 crefmirlimab berdoxam | “Zirconium Zr 89 crefmirlimab berdoxam, the investigational agent proposed in this imaging study, is an anti-CD8 minibody (crefmirlimab)” NCT06863233 ↗ |